Drug Profile
HIV vaccine - Progenics
Alternative Names: HIV gp140 vaccine - Progenics; ProVaxLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Aaron Diamond AIDS Research Center; Progenics Pharmaceuticals; Weill Cornell Medical College
- Developer Progenics Pharmaceuticals
- Class AIDS vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 16 Jun 2020 Progenics Pharmaceuticals has been acquired by Lantheus Holdings
- 15 Mar 2012 Discontinued - Preclinical for HIV infections in USA (Parenteral)
- 23 Nov 2011 HIV vaccine - Progenics is available for licensing as of 09 Nov 2011. http://www.progenics.com